iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) Short Interest Down 72.6% in July

iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) saw a large drop in short interest in the month of July. As of July 31st, there was short interest totaling 15,622 shares, a drop of 72.6% from the July 15th total of 57,108 shares. Currently, 0.3% of the company’s stock are short sold. Based on an average daily volume of 28,692 shares, the days-to-cover ratio is presently 0.5 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in iShares Genomics Immunology and Healthcare ETF stock. Triumph Capital Management purchased a new stake in shares of iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,481 shares of the company’s stock, valued at approximately $35,000.

iShares Genomics Immunology and Healthcare ETF Price Performance

NYSEARCA:IDNA opened at $35.40 on Thursday. iShares Genomics Immunology and Healthcare ETF has a 1-year low of $22.11 and a 1-year high of $35.51. The company has a market capitalization of $208.86 million, a PE ratio of 14.76 and a beta of 0.93. The firm’s 50-day moving average price is $32.38 and its 200-day moving average price is $30.52.

About iShares Genomics Immunology and Healthcare ETF

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.